Video

Dr. Wise on the Development of Precision Medicine in Prostate Cancer

David R. Wise, MD, PhD, assistant professor, Department of Medicine, assistant professor, Department of Urology, NYU Langone’s Perlmutter Cancer Center, discusses ongoing trials at NYU that are investigating precision oncology hypotheses.

David R. Wise, MD, PhD, assistant professor, Department of Medicine, assistant professor, Department of Urology, NYU Langone’s Perlmutter Cancer Center, discusses ongoing trials at NYU that are investigating precision oncology hypotheses.

Two trials are directed at two main genetic features of cancer. The first feature is seen in cancers that have DNA-repair defects; cancers that have the BRCA1/2 gene that are known for their role in causing hereditary ovarian and breast cancer syndrome.

Less known is that men are affected with these syndromes as well. Men who are first-degree male relatives of patients with breast and ovarian cancer are at risk and should undergo genetic testing. Conversely, if tumors are found with those features, earlier phase studies reveal sensitivity to a neuro-class of compounds called PARP inhibitors.

There are two available trials at NYU, both incorporating the PARP inhibitor, rucaparib (Rubraca). In another trial, investigators are coupling a newer PARP inhibitor called talazoparib (BMN-673) with an immunotherapy PD-L1 checkpoint inhibitor with the hope of seeing synergism between the two drugs.

Related Videos
James J. Harding, MD, associate attending physician, Memorial Sloan Kettering Cancer Center
J. Bradley Elder, MD
Rimas V. Lukas, MD
Adam E. Singer, MD, PhD, Health Sciences Clinical Instructor, medicine, division lead, kidney cancer, Division of Hematology/Oncology, UCLA Health
Diane Reidy-Lagunes, MD, vice chair, Oncology Operations, Regional Care Network, Memorial Sloan Kettering Cancer Center
Shubham Pant, MD, MBBS
Kevin Kalinsky, MD, MS, professor, Department of Hematology and Medical Oncology, director, Division of Medical Oncology, Department of Hematology and Medical Oncology, Emory University School of Medicine; Louisa and Rand Glenn Family Chair in Breast Cancer Research, director, Glenn Family Breast Center, director, Breast Medical Oncology, Winship Cancer Institute of Emory University
Brett L. Ecker, MD
Benjamin Garmezy, MD, assistant director, Genitourinary Research, Sarah Cannon Research Institute
Yelena Y. Janjigian, MD, chief, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center